Evolus, Inc. (EOLS)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$9.30+2.76%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · EOLS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||
| Revenues | 316.5 | 297.2 | 266.3 | 202.1 | 148.6 | 99.7 | 56.5 | 34.9 | — |
| Cost of Revenues | 105.3 | 100.1 | 84.0 | 64.5 | 58.8 | 43.5 | 18.3 | 8.0 | — |
| Gross Profit | 211.2 | 197.1 | 182.3 | 137.6 | 89.8 | — | — | 26.9 | — |
| Operating Expenses & Income | |||||||||
| Selling, General & Admin | 216.5 | 220.8 | 198.0 | 164.9 | 141.8 | 112.1 | 98.2 | 113.6 | — |
| R&D Expenses | — | — | — | — | — | 2.1 | 1.7 | 4.0 | 6.5 |
| Operating Income | (18.7) | (32.7) | (34.4) | (49.2) | (65.3) | (44.4) | (153.1) | (98.9) | (46.1) |
| Earnings from Continuing Operations | |||||||||
| Interest Expense | — | 19.7 | 18.7 | 13.8 | 9.1 | 1.4 | — | — | 0.9 |
| Interest & Investment Income | — | — | — | — | — | — | — | — | 0.2 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | 0.7 |
| EBT, Incl. Unusual Items | (33.7) | (51.0) | (49.8) | (61.5) | (74.3) | (46.8) | (162.9) | (105.1) | (46.8) |
| Income Tax Expense | 0.7 | 0.7 | 0.7 | 0.2 | 0.1 | 0.0 | 0.1 | (15.0) | 0.1 |
| Net Income | |||||||||
| Net Income | (34.3) | (51.6) | (50.4) | (61.7) | (74.4) | (46.8) | (163.0) | (90.0) | (46.9) |
| Per Share | |||||||||
| Basic EPS | (0.52) | (0.80) | (0.81) | (1.08) | (1.33) | (0.94) | (4.83) | — | — |
| Diluted EPS | (0.52) | (0.80) | (0.81) | (1.08) | (1.33) | (0.94) | (4.83) | — | — |
| Revenue per Share | 4.80 | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 65.9 | 64.5 | 62.0 | 56.9 | 56.1 | 49.8 | 33.7 | — | — |
| Diluted Weighted Avg Shares | 65.9 | 64.5 | 62.0 | 56.9 | 56.1 | 49.8 | 33.7 | — | — |
| Supplemental | |||||||||
| EBITDA | — | (28.3) | (29.1) | (47.1) | (61.6) | (38.8) | (146.0) | (94.8) | (46.1) |
| EBIT | (18.7) | (32.7) | (34.4) | (49.2) | (65.3) | (44.4) | (153.1) | (98.9) | (46.1) |
| Effective Tax Rate | -1.9% | — | — | -0.3% | -0.1% | -0.1% | -0.0% | 14.3% | -0.1% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.